drugset
Drugs / BI 1358894
last change Feb 2024 re-read 9 days ago

BI 1358894

Small molecule targets TRPC4 via inhibition

Developed for
major depressive disorder · borderline personality disorder · post-traumatic stress disorder
Investigated by
Boehringer Ingelheim

Trials 17

today NCT05934942 · Ph 1 NCT05155306 · Ph 1 NCT05103657 · Ph 2 NCT04899674 · Ph 1 NCT04521478 · Ph 2 NCT04566601 · Ph 2 NCT04567316 · Ph 1 NCT04426851 · Ph 1 NCT04423757 · Ph 2 NCT04099732 · Ph 1 NCT03904576 · Ph 1 NCT03892616 · Ph 1 NCT03875001 · Ph 1 NCT03843151 · Ph 1 NCT03854578 · Ph 1 NCT03754959 · Ph 1 NCT03210272 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 113 trials
Phase 1 NCT05934942 Sep 2023 → Feb 2024 — Boehringer Ingelheim Terminated No outcome recorded
Phase 1 NCT05155306 Jan → May 2022 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04899674 Jun → Sep 2021 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04567316 Oct 2020 → Jan 2021 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04426851 Jul → Oct 2020 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT04099732 Oct → Dec 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03904576 Apr → Aug 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03892616 Apr → Jul 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03875001 Mar → Jul 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 1 NCT03843151 Mar → Jun 2019 — Boehringer Ingelheim Completed No outcome recorded
Phase 24 trials · 4 missed
Phase 2 NCT05103657 Dec 2021 → Oct 2023 post-traumatic stress disorder Boehringer Ingelheim Completed Missed primary
Phase 2 NCT04521478 Nov 2020 → Jan 2024 major depressive disorder Boehringer Ingelheim Completed Missed primary
Phase 2 NCT04566601 Nov 2020 → Dec 2022 borderline personality disorder Boehringer Ingelheim Completed Missed primary
Phase 2 NCT04423757 Jun 2020 → Apr 2022 major depressive disorder Boehringer Ingelheim Terminated Missed primary Stop: Enrollment

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 19 sources stand behind the page.

FieldValueCited text
Known as BI 1358894 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03892616 ↗
16

NCT03210272 ↗

NCT04099732 ↗

NCT03854578 ↗

NCT05103657 ↗

NCT04426851 ↗

NCT04521478 ↗

NCT03754959 ↗

NCT04899674 ↗

NCT04566601 ↗

NCT03904576 ↗

Show 6 more sources
Action Inhibit “BI 1358894, a small-molecule inhibitor of TRPC ion channels, is currently being developed for the treatment of MDD.” PMID 38019355 ↗ Nov 2023
Modality Small molecule “BI 1358894, a small-molecule inhibitor of TRPC ion channels, is currently being developed for the treatment of MDD.” PMID 38019355 ↗ Nov 2023
Route Oral “oral administration of single rising doses” NCT03210272 ↗
Target TRPC4 “TRPC ion channel members 4 and 5 (TRPC4/5)” PMID 38019356 ↗ Nov 2023